Verition Fund Management
SNDX icon

Verition Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Verition Fund Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,460
Closed -$388K – 3428
2025
Q4 		$388K Buy
18,460
+1,281
+7% +$22.3K ﹤0.01% 2848
2025
Q3 		$264K Sell
17,179
-108,166
-86% -$1.42M ﹤0.01% 3357
2025
Q2 		$1.17M Buy
125,345
+90,308
+258% +$994K 0.01% 2355
2025
Q1 		$430K Buy
+35,037
New +$494K ﹤0.01% 2672
2024
Q4 		– Sell
-79,341
Closed -$1.53M – 3502
2024
Q3 		$1.53M Sell
79,341
-65,225
-45% -$1.35M 0.01% 1594
2024
Q2 		$2.97M Sell
144,566
-202,296
-58% -$4.23M 0.02% 1040
2024
Q1 		$8.26M Buy
346,862
+203,596
+142% +$4.54M 0.06% 409
2023
Q4 		$3.1M Buy
143,266
+128,266
+855% +$1.97M 0.02% 632
2023
Q3 		$218K Buy
+15,000
New +$284K ﹤0.01% 1931
2022
Q4 		– Sell
-10,737
Closed -$258K – 2681
2022
Q3 		$258K Buy
+10,737
New +$241K ﹤0.01% 2334
2021
Q1 		– Sell
-88,595
Closed -$1.97M – 1752
2020
Q4 		$1.97M Buy
+88,595
New +$1.84M 0.02% 378

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Verition Fund Management's SNDX Position: Q1 2026 in Review

Verition Fund Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2026, closing a stake of 18,460 shares — an estimated $388K sold.

Verition Fund Management first reported a position in SNDX in Q4 2020 and held it in 11 quarters. The position peaked at $8.26M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Verition Fund Management reported no remaining Syndax Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 18,460 Syndax Pharmaceuticals shares in Q1 2026, an estimated $388K.
  • Verition Fund Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Verition Fund Management's Syndax Pharmaceuticals position peaked at $8.26M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.